Hexarelin: Complete Research Guide & Chemical Profile

Hexarelin (also known as Examorelin and HEX) is a synthetic hexapeptide growth hormone secretagogue with the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂. Its molecular formula is C₄₇H₅₈N₁₀O₆ and it has a molecular weight of 887.04 Da. The peptide was developed as a structural analog of GHRP-6 with modifications at positions 2 and 5 designed to enhance receptor binding affinity and metabolic stability.

The incorporation of D-2-methyltryptophan at position 2 and D-phenylalanine at position 5 confers resistance to enzymatic degradation by endogenous peptidases. The C-terminal amidation further improves stability and receptor interaction. Hexarelin is typically supplied as a white lyophilized powder with a trifluoroacetate (TFA) counterion, and its CAS registry number is 140703-51-1.

• Molecular Formula: C₄₇H₅₈N₁₀O₆
• Molecular Weight: 887.04 Da
• Sequence: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂
• CAS Number: 140703-51-1
• Appearance: White to off-white lyophilized powder
• Solubility: Freely soluble in water and bacteriostatic water
• Storage: -20°C lyophilized; 2-8°C reconstituted (use within 21 days)

Hexarelin exerts its primary biological effects through high-affinity binding to the growth hormone secretagogue receptor type 1a (GHSR-1a), a G-protein-coupled receptor predominantly expressed in the anterior pituitary gland and hypothalamus. GHSR-1a activation triggers a Gq/11-mediated signaling cascade that increases intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG) levels, ultimately elevating cytoplasmic calcium concentrations in somatotroph cells.

This calcium mobilization stimulates the exocytotic release of preformed growth hormone (GH) vesicles from anterior pituitary somatotrophs. Hexarelin binds GHSR-1a with higher affinity than the endogenous ligand ghrelin and demonstrates greater potency than first-generation secretagogues such as GHRP-6 in stimulating GH release. Notably, Hexarelin also activates the CD36 scavenger receptor, which may contribute to its observed cardiovascular effects independent of GH release.

Unlike exogenous GH administration, Hexarelin-stimulated GH release preserves the pulsatile secretion pattern and is subject to negative feedback regulation by somatostatin and IGF-1. This physiological feedback mechanism limits the magnitude of GH elevation and distinguishes secretagogue-mediated stimulation from direct GH replacement.

Hexarelin has been extensively studied for its capacity to stimulate the hypothalamic-pituitary GH axis. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that Hexarelin produces robust, dose-dependent GH release in both animal models and human subjects, with peak GH concentrations observed 15-30 minutes after administration. The GH response to Hexarelin is among the strongest of all synthetic secretagogues studied to date.

Importantly, preclinical studies have demonstrated that repeated Hexarelin administration leads to partial desensitization of the GH response, with diminished peak GH levels observed after sustained exposure. This tachyphylaxis appears to involve receptor downregulation at the pituitary level and increased somatostatin tone. The phenomenon has been a significant area of investigation in understanding GHSR-1a receptor regulation and has implications for experimental protocol design.

In comparative studies, Hexarelin has demonstrated synergistic effects when co-administered with growth hormone-releasing hormone (GHRH), producing GH release significantly greater than either peptide alone. This synergy supports the hypothesis that GHSR-1a agonists and GHRH act through complementary mechanisms: GHRH primarily stimulates GH synthesis and release via the GHRH receptor, while Hexarelin amplifies release and suppresses somatostatin inhibition.

One of the most distinctive aspects of Hexarelin research is its documented cardioprotective activity, which appears to operate independently of GH release. Studies published in Endocrinology and the European Journal of Pharmacology demonstrated that Hexarelin protects cardiomyocytes against ischemia-reperfusion injury in isolated heart models, reduces infarct size, and improves post-ischemic cardiac function.

The cardiac effects of Hexarelin are mediated at least in part through the CD36 receptor (also known as scavenger receptor class B type 3), which is expressed on cardiomyocytes, macrophages, and endothelial cells. CD36 activation by Hexarelin triggers downstream signaling through peroxisome proliferator-activated receptor gamma (PPARγ), leading to anti-inflammatory and anti-apoptotic effects in cardiac tissue. This CD36-dependent pathway is distinct from GHSR-1a signaling and represents a unique pharmacological property of Hexarelin among GH secretagogues.

Additional preclinical research has investigated Hexarelin in models of cardiac fibrosis, where it demonstrated the ability to reduce collagen deposition and attenuate left ventricular remodeling following myocardial injury. These findings have positioned Hexarelin as a compound of interest in cardiovascular research beyond its original characterization as a GH secretagogue.

Emerging research has identified neuroprotective properties of Hexarelin in preclinical models of neuronal injury. Studies in cerebellar granule neurons demonstrated that Hexarelin attenuates apoptotic cell death induced by serum deprivation, with protective effects mediated through activation of the Akt/PKB survival signaling pathway. GHSR-1a is expressed in multiple brain regions including the hippocampus, hypothalamus, and cortex, providing anatomical substrate for direct central nervous system effects.

In experimental models of neurodegenerative conditions, Hexarelin has shown the capacity to reduce oxidative stress markers and preserve mitochondrial membrane potential in neuronal cell cultures exposed to toxic insults. These neuroprotective effects appear to involve both GHSR-1a-dependent and GH-independent mechanisms, though the precise signaling pathways require further elucidation in ongoing research programs.

Hexarelin belongs to the growth hormone-releasing peptide (GHRP) family, which was developed through systematic structure-activity relationship (SAR) studies beginning with met-enkephalin derivatives in the 1970s. The hexapeptide scaffold His-D-Xaa-Ala-Trp-D-Phe-Lys-NH₂ was identified as the optimal framework for GHSR-1a activation, with the D-amino acids at positions 2 and 5 being critical for both receptor binding and proteolytic resistance.

The 2-methyltryptophan modification at position 2 distinguishes Hexarelin from GHRP-6 (which has D-Trp at this position) and contributes to its enhanced binding affinity. Alanine scanning mutagenesis studies have demonstrated that positions 1 (His), 4 (Trp), and 6 (Lys) are essential for receptor activation, while position 3 (Ala) is tolerant of substitution. The C-terminal amide is required for full biological activity; the free acid form shows markedly reduced potency.

Within the GHRP family, Hexarelin is characterized by the highest GH-releasing potency but also the most pronounced tachyphylaxis upon repeated administration. GHRP-2 demonstrates intermediate potency with less desensitization, while Ipamorelin shows the greatest selectivity for GH release with minimal effects on cortisol and prolactin. GHRP-6 retains the strongest appetite-stimulating properties through ghrelin-mimetic activity.

• Hexarelin: Highest GH potency, significant cardiac effects via CD36, notable tachyphylaxis
• GHRP-6: Moderate GH release, strong appetite stimulation, fewer cardiac effects
• GHRP-2: Strong GH release, moderate cortisol/prolactin elevation, less desensitization
• Ipamorelin: Selective GH release, minimal cortisol/prolactin effects, least tachyphylaxis
• MK-677 (Ibutamoren): Orally bioavailable non-peptide GHSR-1a agonist, sustained GH elevation

The unique CD36-mediated cardiac activity of Hexarelin is not shared by other members of the GHRP family and represents a distinguishing pharmacological feature that has driven substantial interest in cardiovascular research applications. This dual receptor engagement (GHSR-1a and CD36) makes Hexarelin pharmacologically distinct from all other growth hormone secretagogues.

Lyophilized Hexarelin is stable for 24-36 months when stored at -20°C protected from light and moisture. The peptide should be allowed to equilibrate to room temperature before opening to prevent moisture condensation on the lyophilized cake. Reconstitution is performed by adding bacteriostatic water or sterile water slowly along the vial wall, allowing the powder to dissolve without agitation. Vigorous shaking should be avoided as it may cause aggregation and surface adsorption.

Reconstituted Hexarelin solutions should be stored at 2-8°C and used within 21 days when prepared with bacteriostatic water, or within 48 hours when prepared with sterile water lacking preservative. For long-term storage of reconstituted material, aliquoting into single-use volumes and storing at -20°C is recommended to minimize freeze-thaw cycles. The peptide is stable across a pH range of 3.0-7.0, with optimal stability near pH 5.0.

• Lyophilized storage: -20°C, protected from light, 24-36 months
• Reconstitution solvent: Bacteriostatic water (0.9% benzyl alcohol)
• Reconstituted storage: 2-8°C for up to 21 days
• Avoid repeated freeze-thaw cycles
• Allow vial to reach room temperature before opening
• Add solvent slowly along vial wall; do not vortex

Analytical verification of Hexarelin identity and purity requires reverse-phase HPLC and mass spectrometry. HPLC analysis using a C18 column with acetonitrile/water gradient containing 0.1% TFA typically yields a single dominant peak with retention time dependent on specific chromatographic conditions. Purity specification for research-grade Hexarelin is ≥98% by HPLC area normalization.

Mass spectrometric confirmation should show [M+H]⁺ at m/z 888.05 (monoisotopic) with ESI-MS, or the corresponding multiply charged species. The observed molecular weight must match the theoretical value of 887.04 Da within the instrument tolerance (typically ±0.5 Da for standard ESI-MS). Additional quality parameters include amino acid analysis for composition verification, appearance assessment of the lyophilized cake, and endotoxin testing (LAL assay, specification <0.25 EU/mg) for material intended for cell culture or in vivo research.

The following peer-reviewed publications provide foundational and current research on Hexarelin. Researchers are encouraged to consult these primary sources for detailed experimental protocols and data interpretation.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: Growth Hormone Secretagogues Explained: How Ipamorelin, CJC-1295 and GHRP-6 Work → https://www.chemverify.com/learn/growth-hormone-secretagogues-explained-ipamorelin-cjc1295
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism